Keybanc Maintains Overweight on ResMed, Raises Price Target to $267
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $255 to $267.
Stocks · News reference
ResMed Announces $450M Accelerated Share Repurchase Agreement With Citibank
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000943819/000119312526378487/d530283d8k.htm
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ResMed shares are trading higher after Rothschild & Co. initiated coverage on the stock with a Neutral rating and announced a $230 price target.
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230
Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.